Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2002 2
2004 1
2005 1
2006 1
2008 2
2010 2
2011 2
2012 4
2013 4
2014 9
2015 6
2016 3
2017 6
2018 2
2019 3
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

54 results
Results by year
Filters applied: . Clear all
Page 1
Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML. Pejnovic N, et al. World J Gastroenterol. 2016 Nov 28;22(44):9706-9717. doi: 10.3748/wjg.v22.i44.9706. World J Gastroenterol. 2016. PMID: 27956794 Free PMC article. Review.
Galectin-3 (Gal-3), a unique chimera-type β-galactoside-binding protein of the galectin family has a regulatory role in immunometabolism and fibrogenesis. Mice deficient in Gal-3 develop pronounced adiposity, hyperglycemia and hepatic steatosis,
Galectin-3 (Gal-3), a unique chimera-type β-galactoside-binding protein of the galectin family has a regulatory
An update on the recent advances in antifibrotic therapy.
Tacke F, Weiskirchen R. Tacke F, et al. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1143-1152. doi: 10.1080/17474124.2018.1530110. Epub 2018 Oct 3. Expert Rev Gastroenterol Hepatol. 2018. PMID: 30261763 Review.
Fibrosis might progress to cirrhosis and predisposes to hepatocellular carcinoma (HCC), but is also associated with extrahepatic morbidity and mortality in NAFLD/NASH. ...Other antifibrotic drug candidates target cell death or inflammation, such as caspase (emricasan) or A …
Fibrosis might progress to cirrhosis and predisposes to hepatocellular carcinoma (HCC), but is also associated with extrahepatic morb …
Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.
Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, Narimatsu H, Mizokami M. Shirabe K, et al. J Gastroenterol. 2018 Jul;53(7):819-826. doi: 10.1007/s00535-017-1425-z. Epub 2018 Jan 9. J Gastroenterol. 2018. PMID: 29318378 Review.
M2BPGi predicts the development of hepatocellular carcinoma (HCC) in patients infected with hepatitis B and C as well as the prognosis of liver cirrhosis in those with HCC after therapy. ...Hepatic stellate cells (HSCs) secrete M2BPGi, which may serve as a messenger …
M2BPGi predicts the development of hepatocellular carcinoma (HCC) in patients infected with hepatitis B and C as well as the prognosi …
Quantitative proteomics reveal the anti-tumour mechanism of the carbohydrate recognition domain of Galectin-3 in Hepatocellular carcinoma.
Wang M, Tian F, Ying W, Qian X. Wang M, et al. Sci Rep. 2017 Jul 12;7(1):5189. doi: 10.1038/s41598-017-05419-5. Sci Rep. 2017. PMID: 28701735 Free PMC article.
Hepatocellular carcinoma (HCC) is a serious threat to human health. The carbohydrate recognition domain of Galectin-3 (Gal3C) has been reported to be an anti-tumour molecule. ...Of the differentially expressed proteins, CLU, NDRG1, CD166, S100A11 and Galec
Hepatocellular carcinoma (HCC) is a serious threat to human health. The carbohydrate recognition domain of Galectin-3 (
Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma.
Eisa NH, Ebrahim MA, Ragab M, Eissa LA, El-Gayar AM. Eisa NH, et al. J Oncol Pharm Pract. 2015 Oct;21(5):323-30. doi: 10.1177/1078155214532698. Epub 2014 Apr 24. J Oncol Pharm Pract. 2015. PMID: 24769518
In addition, galectin-3 level significantly increased in HCC patients with poor prognosis suffering from portal vein invasion (P = 0.014). ...CONCLUSION: MMP-9 and galectin-3 could be used as a guide for prognosis of HCC since they may play a role in H …
In addition, galectin-3 level significantly increased in HCC patients with poor prognosis suffering from portal vein invasion …
Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma.
Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L, Pan QZ, Xia JC. Jiang SS, et al. J Transl Med. 2014 Sep 27;12:273. doi: 10.1186/s12967-014-0273-3. J Transl Med. 2014. PMID: 25260879 Free PMC article.
We aimed to clarify if expression of galectin-3 is related to the clinicopathological characteristics and prognosis of hepatocellular carcinoma (HCC) patients, and to explore the possible mechanisms of galectin-3 in hepatocellular carcino …
We aimed to clarify if expression of galectin-3 is related to the clinicopathological characteristics and prognosis of hepa
Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation.
Serizawa N, Tian J, Fukada H, Baghy K, Scott F, Chen X, Kiss Z, Olson K, Hsu D, Liu FT, Török NJ, Zhao B, Jiang JX. Serizawa N, et al. Lab Invest. 2015 Oct;95(10):1145-56. doi: 10.1038/labinvest.2015.77. Epub 2015 Jul 6. Lab Invest. 2015. PMID: 26146960 Free PMC article.
Hepatocellular carcinoma (HCC) carries a poor prognosis with no effective treatment available other than liver transplantation for selected patients. ...Galectin 3 was upregulated in the wild-type HCC tumor tissue, but not in the surrounding parenchyma
Hepatocellular carcinoma (HCC) carries a poor prognosis with no effective treatment available other than liver transplantation
[Serum and tissue expressions of galectin-3 in hepatocellular carcinoma and the clinical significances].
Fang QQ, Ni RZ, Xiao MB, Jiang F, Lu CH. Fang QQ, et al. Zhonghua Gan Zang Bing Za Zhi. 2011 Jul;19(7):527-31. doi: 10.3760/cma.j.issn.1007-3418.2011.07.014. Zhonghua Gan Zang Bing Za Zhi. 2011. PMID: 22152245 Chinese.
OBJECTIVE: To study the expression of Galectin-3 in human hepatocellular carcinoma (HCC) tissues and the clinical value of serum Galectin-3 in the diagnosis of hepatocellular carcinoma. ...The relationship between expression levels of …
OBJECTIVE: To study the expression of Galectin-3 in human hepatocellular carcinoma (HCC) tissues and the clinical value …
Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis.
Jeftic I, Jovicic N, Pantic J, Arsenijevic N, Lukic ML, Pejnovic N. Jeftic I, et al. Mol Med. 2015 May 22;21(1):453-65. doi: 10.2119/molmed.2014.00178. Mol Med. 2015. PMID: 26018806 Free PMC article.
The importance of Galectin-3 (Gal-3) in obesity-associated liver pathology is incompletely defined. To dissect the role of Gal-3 in fibrotic nonalcoholic steatohepatitis (NASH), Gal-3-deficient (LGALS3(-/-)) and wild-type (LGALS3(+/+)) C5 …
The importance of Galectin-3 (Gal-3) in obesity-associated liver pathology is incompletely defined. To dissect t …
Galectin-3 regulates hepatic progenitor cell expansion during liver injury.
Hsieh WC, Mackinnon AC, Lu WY, Jung J, Boulter L, Henderson NC, Simpson KJ, Schotanus B, Wojtacha D, Bird TG, Medine CN, Hay DC, Sethi T, Iredale JP, Forbes SJ. Hsieh WC, et al. Gut. 2015 Feb;64(2):312-21. doi: 10.1136/gutjnl-2013-306290. Epub 2014 May 16. Gut. 2015. PMID: 24837171
Galectin-3 (Gal-3) is a β-galactoside-binding lectin that binds to laminin and is expressed in injured liver in mice and humans. DESIGN: We examined the role of Gal-3 in HPC activation. HPC activation was studied following dietary induced hep
Galectin-3 (Gal-3) is a β-galactoside-binding lectin that binds to laminin and is expressed in injured liver in
54 results
Jump to page
Feedback